8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cancer & Tumors242 citations

Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer

Bioeffects Seen

Authors not listed · 1982

Share:

Low nighttime melatonin strongly correlates with estrogen receptor positive breast tumors, highlighting melatonin's protective role against hormone-sensitive cancers.

Plain English Summary

Summary written for general audiences

Researchers measured melatonin levels in 20 women with early-stage breast cancer and found that those with estrogen receptor positive tumors had significantly lower nighttime melatonin peaks compared to healthy controls. The study revealed a strong correlation between low melatonin and high estrogen receptor concentrations in tumors, suggesting melatonin deficiency may play a role in hormone-sensitive breast cancer development.

Why This Matters

This 1982 study reveals a crucial connection that's particularly relevant to our modern EMF environment. The science demonstrates that artificial light at night suppresses melatonin production, and we now know that EMF exposure from wireless devices can similarly disrupt this critical hormone. What makes this finding especially concerning is that melatonin isn't just important for sleep - it's one of our body's most powerful antioxidants and appears to offer protection against hormone-sensitive cancers. The reality is that our 24/7 connected lifestyle, with its constant EMF exposure and blue light from screens, creates the perfect storm for melatonin disruption. When you consider that breast cancer rates have risen dramatically since the widespread adoption of wireless technology, this early research takes on new significance in understanding how our electromagnetic environment may be contributing to cancer risk.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (1982). Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.
Show BibTeX
@article{decreased_nocturnal_plasma_melatonin_peak_in_patients_with_estrogen_receptor_positive_breast_cancer_ce2277,
  author = {Unknown},
  title = {Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer},
  year = {1982},
  doi = {10.1126/SCIENCE.7079745},
  
}
DOI: 10.1126/SCIENCE.7079745PubMed: 7079745

Quick Questions About This Study

The study found women with the lowest nighttime melatonin peaks had tumors with the highest estrogen receptor concentrations, suggesting melatonin levels could potentially serve as an indicator for this specific type of breast cancer.
Half of the breast cancer patients studied (10 out of 20) had estrogen receptor positive tumors and showed significantly lower nocturnal melatonin increases compared to healthy control subjects in this research.
The research revealed a significant correlation between peak plasma melatonin concentration and tumor estrogen receptor concentration in 19 of 20 patients, suggesting melatonin deficiency may contribute to hormone-driven cancer development.
Yes, the study included women with both clinical stage I and stage II breast cancer, indicating that melatonin disruption patterns appear in early-stage disease before cancer has spread significantly.
While the study shows correlation, researchers suggest low melatonin could have 'etiologic significance,' meaning it may actually contribute to causing estrogen receptor positive breast cancer rather than just being a marker.